Hepatocyte growth factor measurement in AL amyloidosis |
| |
| Authors: | Julie Abraham Estelle Desport Charlotte Rigaud Benoit Marin Sébastien Bender Corinne Lacombe |
| |
| Affiliation: | 1. Service d'Hématologie Clinique, Centre National de Référence Amylose AL, CHU, Limoges, France,;2. Service de Néphrologie, Centre National de Référence Amylose AL, CHU, Poitiers, France,;3. CHU Limoges, Centre d'Epidémiologie de Biostatistique et de Méthodologie de la Recherche, France,;4. Service d'Immunologie et d’Immunogénétique, CHU, Limoges, France, and;5. UMR CNRS 7276, Centre National de la Recherche Scientifique, Université de Limoges, Limoges, France |
| |
| Abstract: | Hepatocyte growth factor (HGF) is a pro-angiogenic cytokine activated by tissue-type plasminogen activator (tPA) that might play a role in the progression of multiple myeloma (MM). Preliminary studies indicated that serum HGF levels were higher in patients with AL amyloidosis (AL) compared to those with MM. The aim of the present study was to determine whether HGF is a relevant marker of diagnosis and prognosis in AL. HGF serum levels were measured at diagnosis in patients with monoclonal gammopathy (MG) without AL (76 controls), or with biopsy-proven systemic AL (69 patients). HGF serum levels were significantly higher in patients with AL compared to controls, respectively, 11.2?ng/mL [min: 0.95–max: 200.4] versus 1.4?ng/mL [min: 0.82–max: 6.2] (p?
|
| |
| Keywords: | Amyloidosis hepatocyte growth factor monoclonal gammopathy |
|
|
